Drugs

‘Objectionable Conditions’ at Ukraine Clinical Test Site

A 9/13-9/14 FDA inspection at a clinical test site maintained by a physician in Kyiv, Ukraine, conducted as part of the agency’s Bioresearch Monitoring Program, found “objectionable conditions.” A 12/21/21 Warning Letter says it appears that the site did not adhere to statutory and regulatory requirements.

The letter says the site failed to retain records required to be maintained for two years following the date a marketing application is approved for the drug for the indication for which the drug is being investigated.

Although the doctor in charge indicated to FDA a decision to no longer participate in clinical trials, the agency said it should still receive details on how records will be properly maintained should the site decide to participate as a clinical investigator in the future.

“Your failure to retain study records as required by FDA regulations significantly compromises the validity and integrity of data collected at your site,” the letter concludes.

The physician was told to respond with a list of specific actions taken to prevent similar violations in the future.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome